Davies Angela, Gandara David R, Lara Primo, Goldberg Zelanna, Roberts Peter, Lau Derick
Division of Hematology/Oncology, University of California Davis Cancer Center, Sacramento, CA 95817-2229, USA.
Semin Oncol. 2002 Jun;29(3 Suppl 12):10-6. doi: 10.1053/sonc.2002.34257.
In the treatment of locally advanced (stage III) non-small cell lung cancer, randomized clinical trials have shown that sequential administration of platinum-based chemotherapy followed by radiotherapy improves outcome compared with radiotherapy alone. More recently, concurrent chemoradiotherapy has been shown to be superior to sequential therapy. Incorporating full-dose chemotherapy into induction or consolidation phases is aimed at the eradication of distant micrometastases. These approaches are currently being examined in clinical trials. The role of neoadjuvant and adjuvant therapy in resectable stage IIIA patients remains controversial. Integration of newer cytotoxic agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) and molecularly targeted agents into the treatment of stage-III patients may result in improved long-term outcomes and is currently under study.
